IGMS

Companies
NASDAQ
Igm Biosciences Inc.
Health Care
Price Chart
Overview

About IGMS

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Market Cap
$485.2M
Volume
166.5K
Avg. Volume
185.9K
P/E Ratio
-0.49166662
Dividend Yield
0.00%
Employees
235.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
1.61
High Correlation
Volatility
High (1.00)
Relative to market

Macro Factor Sensitivities

Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for IGMS.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, IGMS shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$485.2M
Volume166.5K
P/E Ratio-0.49
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 14, 2025

PortfolioPilot Analysis

Get AI-powered insights on how IGMS fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025